Recently, Haier International Cell Bank organoid research project has made new progress, and the R&D team members have published 4 high-quality SCI** articles in multiple SCI journals and magazines, with a total impact factor of 239。
4 ** articles were published separatelysciencedirect、hindawi、biomedicine& pharmacotherapy、internationaljournal of biological scienceFocusing on important areas such as the mechanism of cell preparation of organoids, nano-cancer vaccines, organoid customization and related drug research and development, the latest achievements of Haier International Cell Bank in the field of organoid research were shown. **The corresponding authors are all members of the R&D team of the Haier International Cell Bank Organoid Project.
Click image for full size.
OrganoidsAn important tool for disease research and drug developmentOrganoidsIt is not a human organ in the true sense, but an tissue analogue with a certain spatial structure formed by using adult stem cells or pluripotent stem cells for in vitro three-dimensional (3D) culture, which is highly similar to the best tissues or organs in vivo, and can show the interaction and spatial position morphology between cells and cells, cells and their surrounding matrix, and it itself has similar physiological responses to differentiated tissues and organs in vivo.
Compared with the traditional 2D cell culture mode, 3D cultured organoids contain a variety of cell types, which can form functional "micro-organs", which are less different from the human body, and can be better used to simulate the occurrence process and physiological and pathological state of organs and tissues, so they have broad application prospects in basic research and clinical diagnosis and treatment.
Organoids are widely used.
Because organoids can highly mimic the physiological structure and function of orthotopic tissues, they can stably maintain the characteristics of tumor cells in vivo, and have the advantages of easy operation, fast speed, high throughput, high clinical relevance, and wide application, and are also suitable for tumor drug screening and personalization**.
Haier International Cell BankIntegrate with the international frontier and gather innovative resourcesHaier International Cell Bank has been committed to technology research and development and industrialization innovation in the field of biology. Due to the great advantages and broad prospects of the combination of stem cells and organoid technology in the clinical field, in recent years, Haier International Cell Bank has also increased research investment in this field, built an industry-university-research platform, and accelerated the transformation of organoid scientific research achievements and cutting-edge technologies.
In April 2021, Haier International Cell Bank joined hands with Academician Kim Namheng of the Korean Academy of Science and Technology to carry out cooperation in various fields such as organoids and animal models of major diseases, and established the Shandong Academician Workstation in October of that year. Academician Jin was stationed in the academician workstation as a distinguished expert of Haier International Cell Bank.
Dr. Cao Qilong, Vice President of R&D of Haier International Cell Bank, and Academician Jin Nanheng jointly unveiled the Shandong Academician Workstation.
Academician Jin on the left).
In the same year, Haier International Cell Bank applied for the "Double Hundred Foreign Experts" program of Shandong Province for the project of "Development of Drug Screening Technology System Based on Liver Tumors and Brain Organoids", which was approved.
In 2023, the company will cooperate with Dr. Han Zhongzhong of South Korea's Nexel Biotechnology Co., Ltd., Professor Han Dongxu of OrganoidSciences and other experts in the industry to actively promote the industry-university-research cooperation mechanism and promote the faster development of regional organoid technology. In May, Haier International Cell Bank signed a strategic cooperation agreement with NEXEL, and reached a technical service cooperation on HIPSC-derived cardiomyocytes in December. Haier International Cell Bank has received greater assistance in the fields of related cell technology research and development, drug research and development, and organoid research.
Dr. Cao Qilong and Dr. Han Zhongzhong signed a cooperation agreement on HIPSC-derived cardiomyocyte technology services on behalf of both parties.
In recent years, Haier International Cell Bank has given full play to its advantages in talents, scientific research, management system and other aspects, and has achieved positive results in serving the local community, co-construction of industry, university and research, independent research and development of core technologies, and improving the modernization level of the industrial chainNational High-tech Enterprise, Shandong Academician Workstation, Shandong Province Excellent New R&D Institution, Qingdao Stem Cell Drug R&D Excellent Expert Workstation, Qingdao Key Laboratory of Stem Cell and Regenerative Medicine, Qingdao Cell Technology Development and Transformation Technology Innovation Center and many other scientific research platform qualification certifications
With continuous investment, Haier International Cell Bank has also achieved rapid development in R&D team building and innovation resource gathering, with an existing scientific research team of more than 200 people and nearly 100 high-level talents with doctoral and master's degrees. In recent years, the team has also gained a lot in intellectual property rights, and has published 31 articles in SCI journals with a total impact factor of 15537；1 international patent has been approved, and 17 invention patents have been applied, of which 3 have been authorized. 54 utility model patents have been applied for and authorized.
Haier International Cell Bank continues to make progress in the field of organoids, which will also promote the company to make greater achievements in the research and development of stem cell models for major diseases. Haier International Cell Bank will continue to adhere to high-quality scientific research, cooperate with world-class scientific research teams, further deepen the research on organoids, and strive to usher in more new breakthroughs to bring profound changes to human health and quality of life.